The Necessity of Considering Serotonin Toxicity as a Differential Diagnosis for NMS-Like Symptoms

Abstract

Get full access to this article

View all access options for this article.

References

Stoner

Berry

. Suspected neuroleptic malignant syndrome during quetiapine-clozapine cross-titration. J Pharm Pract. [Epub ahead of print, March 24, 2009] doi:10.1177/0897190009333412.

Strawn

Keck

Jr Caroff

. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870–876.

Ananth

Aduri

Parameswaran

Gunatilake

. Neuroleptic malignant syndrome: Risk factors, pathophysiology, and treatment. Acta Neuropsychiatrica. 2004;16:219–228.

Birmes

Coppin

Schmitt

Lauque

. Serotonin syndrome: a brief review. CMAJ. 2003;168:1439–1442.

Odagaki

. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf. 2009;4:84–93.

Kaufman

Levitt

Schiltz

Sunderram

. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: Case analysis. Ann Clin Psychiatry. 2006;18:201–204.

Gurrera

. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169–180.